Research Day

Penn Dental Medicine Research Day 2019 will be Thursday, May 16, 2019.

Research Day 2019

Penn Dental Medicine will once again bring faculty and students together to share their research activities with one another and spotlight the depth of the School’s research enterprise at Research Day 2019, to be held May 16 at Penn Dental Medicine.

The day will include a program of presentations by faculty and two invited speakers, along with poster presentations, representing DMD-student and faculty and junior investigator research.

In addition, student and junior investigator research will be recognized with the selection of the 2019 AADR Travel Grants. The AADR Travel Grant program was launched by Penn Dental Medicine in 2014 to build opportunities to advance ongoing research and leadership among students and junior researchers; this year’s recipients will attend and be encouraged to present their work at the 2020 IADR/AADR/CADR General Session to be held in Washington, DC, in March of 2020.

Register Now»

*Registration closes on May 14 at 11:59 PM

Research Day 2019 Schedule

Research Day 2019 Schedule

8:00 am Check-in and Breakfast
8:30 am Welcome

Dana T. Graves, Vice Dean for Research and Scholarship

Frank Setzer, Chair, Penn Dental Medicine Research Day

8:45 am Role for GAR1 in regulation of the DNA damage response

Faizan Alawi, DDS

10 am Coffee Break
10:15 am Veteran’s Affairs Medical Center Retrospective Implant Database

Neeraj Panchal, DDS, MD, MA

10:35 am Biologics in Oral Medicine: Evidence for use in Sjögren’s syndrome, pemphigus, and pemphigoid as analyzed through the World Workshop on Oral Medicine VII

Katherine France, DMD, MS

10:55 am Changes in Salivary Pro-Inflammatory Cytokine Levels Following Oral Care Intervention in Cancer Patients with Mucositis

Patricia Corby, DDS, MS

11:30 am PDM Research Day Keynote Lecture

The Role of Osteoclasts in MRONJ Pathophysiology

Reuben Kim, DDS, PhD, Chair and Associate Professor, Section of Restorative Dentistry, Director of Research Collaborative Programs, Division of Constitutive & Regenerative, UCLA School of Dentistry

12:30 pm Lunch
1:30 pm Presentation of the Joseph and Josephine Rabinowitz Award for Excellence in Research
1:45 pm Joseph L. Rabinowitz Memorial Lecture

Biomedical R&D Innovation: Every Life Saved Is a Miracle
Walter H. Moos, PhD, CEO of ShangPharma Innovation

2:30 pm Poster Presentation and Poster Competition
4:30-6 pm Award Ceremony/Reception

Chair and Associate Professor, Section of Restorative Dentistry
Director, Restorative Advanced Clinical Training (ACT) Program
UCLA School of Dentistry

Reuben Kim is Chair and Associate Professor in the Section of Restorative Dentistry and the Director for Collaborative Research Programs in the Division of Constitutive & Regenerative Sciences at UCLA School of Dentistry. Dr. Kim also holds a dual appointment with the Section of Oral Biology. Dr. Kim is also an active practitioner in the UCLA Faculty Group Dental Practice as a restorative dentist. Dr. Kim holds a DDS and PhD from the University of California, Los Angeles.

Dr. Kim’s research interests lies in; 1) the role of osteomucosal healing in ONJ development by bisphosphonate and denosumab, 2) the role of epigenetics in aging and HPV-associated oral carcinogenesis, and 3) mechanisms of pulp regeneration in the context of reparative dentin formation. Based on clinical experiences and observations, our laboratory developed animal models that recapitulate multiple disease entities, including ONJ lesions, oral cancer development, and direct pulp capping, to examine the underlying pathophysiology at the preclinical level. Our lab also utilizes in vitro cell culture system and various biochemical techniques to elucidate the fundamental mechanisms at the molecular level.

Managing Director, Pandect Bioventures
CEO, ShangPharma Innovation

Dr. Walter Moos is Managing Director of Pandect Bioventures, a venture capital firm, bringing more than three decades of experience in executive roles in pharmaceutical and biotechnology organizations. He also serves as CEO of ShangPharma Innovation, a venture incubator and innovation ecosystem. He previously served as president of SRI Biosciences (Stanford Research Institute), where he worked closely with academic, industry, and government partners to bring new medicines and devices closer to market. Prior to this, he was chairman and CEO of MitoKor (Migenix) and a vice president of R&D at Chiron (Novartis) and Warner-Lambert/Parke-Davis (Pfizer).

Over the course of his career, Dr. Moos has served on numerous boards and as an advisor to government, nonprofit, and for-profit organizations. His boards have included Aprinoia Therapeutics, Axiom Biotechnologies (Sequenom), the Biotechnology Industry Organization
(BIO), Circle Pharma, the Critical Path Institute, Global Blood Therapeutics, Keystone Symposia, Mimotopes (ThermoFisher), Oncologic (Aduro), Onyx (Amgen), Rigel Pharma, and Valitor. Multiple drugs have reached patients through his guidance.

Dr. Moos has held faculty positions at several major universities, including serving as an adjunct full professor of pharmaceutical chemistry at the University of California, San Francisco since 1992. He has served as a consultant to industry in North America, Europe, and Asia, and has worked as an advisor or committee member for many organizations, including the U.S. National Academy of Sciences. He has co-founded several scientific journals, co-authored or edited 6 books, and has more than 170 publications and patents. He holds an A.B. in chemistry from Harvard University and a Ph.D. in chemistry from the University of California, Berkeley.

Interested in attending Penn Dental Medicine? Admissions